SV2004001226A - Uso de una combinacion de compuestos en un inhalador de polvo seco, ref. pcs 25280 - Google Patents

Uso de una combinacion de compuestos en un inhalador de polvo seco, ref. pcs 25280

Info

Publication number
SV2004001226A
SV2004001226A SV2002001226A SV2002001226A SV2004001226A SV 2004001226 A SV2004001226 A SV 2004001226A SV 2002001226 A SV2002001226 A SV 2002001226A SV 2002001226 A SV2002001226 A SV 2002001226A SV 2004001226 A SV2004001226 A SV 2004001226A
Authority
SV
El Salvador
Prior art keywords
combination
compounds
formulation
formula
pcs
Prior art date
Application number
SV2002001226A
Other languages
English (en)
Inventor
Michael John Mumphrey
Paul Robert Miller
Michael Trevor Shepherd
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SV2004001226A publication Critical patent/SV2004001226A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Abstract

LA PRESENTE INVENSION SE REFIERE A UNA FORMULACION DE INHALACION QUE COMPRENDE UNA COMBINACION DE UN COMPUESTO SELECCIONADO ENTRE UNA CLASE PARTICULAR DE 5, 6-DIHIDRO-9H-PIRAZOLO[3,4-c] -1,2,4-TRIAZOLO [4, 3-a] PIRIDINAS DE FORMULA (I) Y UNA SAL TIOTROPIO O SOLVATO DE CUALQUIERA DE ELLOS, QUE ES CAPAZ DE LIBERAR EL COMPUESTO DE FORMULA (I) EN FORMA DE PARTICCULAS SOLIDAS FINAS EN EL PULMON. LA INVENCION TAMBIEN INCLUYE EL USO DE TAL FORMULACION EN EL TRATAMIENTO DE CIERTAS ENFERMEDADES TALES COMO LAS ENFERMEDADES TALES FORMULACIONES ES POSIBLE ELIMINAR LA RESPUESTA DE TOS INDESEADA ASOCIADA CON EL USO DE LOS COMPUESTOS DE FORMULA (I) EN INHALADORES DE DOSIS MEDIDA DE SOLUCION, PUDIENDO AFECTAR NEGATIVAMENTE TAL RESPUESTA A LA ADMINISTRACION DE UNA DOSIS TERAPEUTICAMENTE EFICAZ Y A LARGO PLAZO, IMPEDIR EL CUMPLIMIENTO DEL TRATAMIENTO POR PARTE DEL PACIENTE.
SV2002001226A 2001-09-12 2002-09-12 Uso de una combinacion de compuestos en un inhalador de polvo seco, ref. pcs 25280 SV2004001226A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0122031.8A GB0122031D0 (en) 2001-09-12 2001-09-12 Use of pde4 inhibitors in a dry powder inhaler

Publications (1)

Publication Number Publication Date
SV2004001226A true SV2004001226A (es) 2004-02-24

Family

ID=9921954

Family Applications (2)

Application Number Title Priority Date Filing Date
SV2002001227A SV2004001227A (es) 2001-09-12 2002-09-12 Uso de compuestos en un inhalador de polvo seco ref. pcs22028
SV2002001226A SV2004001226A (es) 2001-09-12 2002-09-12 Uso de una combinacion de compuestos en un inhalador de polvo seco, ref. pcs 25280

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SV2002001227A SV2004001227A (es) 2001-09-12 2002-09-12 Uso de compuestos en un inhalador de polvo seco ref. pcs22028

Country Status (34)

Country Link
US (3) US20030064031A1 (es)
EP (1) EP1427414A1 (es)
JP (1) JP2005505560A (es)
KR (1) KR20040036940A (es)
CN (1) CN1553801A (es)
AP (2) AP2002002623A0 (es)
AR (2) AR036474A1 (es)
BG (1) BG108569A (es)
BR (1) BR0212449A (es)
CA (1) CA2457717A1 (es)
CZ (1) CZ2004310A3 (es)
EA (1) EA006742B1 (es)
EC (1) ECSP045018A (es)
EE (1) EE200400078A (es)
GB (1) GB0122031D0 (es)
HN (2) HN2002000253A (es)
HR (1) HRP20040162A2 (es)
HU (1) HUP0401890A3 (es)
IL (1) IL160380A0 (es)
IS (1) IS7151A (es)
MA (1) MA27062A1 (es)
MX (1) MXPA04002354A (es)
NO (1) NO20041011L (es)
NZ (1) NZ530929A (es)
OA (1) OA12660A (es)
PA (2) PA8554601A1 (es)
PE (2) PE20030509A1 (es)
PL (1) PL368736A1 (es)
SK (1) SK1272004A3 (es)
SV (2) SV2004001227A (es)
TN (1) TNSN04040A1 (es)
TW (1) TW200602054A (es)
WO (2) WO2003022275A1 (es)
ZA (1) ZA200401002B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176391A1 (en) * 2002-12-31 2004-09-09 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
WO2007036029A1 (en) * 2005-09-28 2007-04-05 Merck Frosst Canada Ltd. Aerosol powder formulation comprising sieved lactose
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR200909788A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
AP2015008663A0 (en) 2013-02-19 2015-08-31 Pfizer Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
KR20150076005A (ko) 2013-12-26 2015-07-06 삼성디스플레이 주식회사 액정 표시 장치
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
CU20170007A7 (es) 2014-08-06 2017-06-05 Pfizer Compuestos de imidazopiridazina
CN111249260B (zh) * 2014-09-15 2023-01-10 维罗纳制药公司 包含rpl554的液体吸入制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004974A (en) * 1995-06-06 1999-12-21 Pfizer Inc Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren

Also Published As

Publication number Publication date
EA200400301A1 (ru) 2004-06-24
HN2002000254A (es) 2003-04-07
SV2004001227A (es) 2004-02-24
CA2457717A1 (en) 2003-03-20
PA8554601A1 (es) 2003-09-17
TW200602054A (en) 2006-01-16
NO20041011L (no) 2004-03-10
IL160380A0 (en) 2004-07-25
BR0212449A (pt) 2004-08-17
WO2003022275A1 (en) 2003-03-20
CZ2004310A3 (cs) 2005-02-16
CN1553801A (zh) 2004-12-08
KR20040036940A (ko) 2004-05-03
BG108569A (bg) 2005-02-28
US20050232871A1 (en) 2005-10-20
IS7151A (is) 2004-02-13
AP2002002624A0 (en) 2002-09-30
PL368736A1 (en) 2005-04-04
NZ530929A (en) 2006-08-31
HUP0401890A2 (hu) 2004-12-28
AR036473A1 (es) 2004-09-08
EA006742B1 (ru) 2006-04-28
AP2002002623A0 (en) 2002-09-30
OA12660A (en) 2006-06-19
ZA200401002B (en) 2005-02-07
WO2003022279A1 (en) 2003-03-20
MA27062A1 (fr) 2004-12-20
PA8554701A1 (es) 2003-09-17
HRP20040162A2 (en) 2004-08-31
TNSN04040A1 (fr) 2006-06-01
SK1272004A3 (sk) 2005-03-04
HN2002000253A (es) 2003-04-07
GB0122031D0 (en) 2001-10-31
AR036474A1 (es) 2004-09-08
US20030064031A1 (en) 2003-04-03
JP2005505560A (ja) 2005-02-24
MXPA04002354A (es) 2004-06-29
HUP0401890A3 (en) 2008-03-28
EP1427414A1 (en) 2004-06-16
EE200400078A (et) 2004-06-15
PE20030443A1 (es) 2003-05-17
US20030064034A1 (en) 2003-04-03
PE20030509A1 (es) 2003-06-23
ECSP045018A (es) 2004-04-28

Similar Documents

Publication Publication Date Title
SV2004001226A (es) Uso de una combinacion de compuestos en un inhalador de polvo seco, ref. pcs 25280
ES2147294T3 (es) Compuestos terapeuticos.
NI201800102A (es) Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1, 5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
AR039947A1 (es) Formulacion farmaceutica que comprende nicotina
BRPI0510862A (pt) medicamento para tratar disfunção sexual em um paciente, medicamento para tratar disfunção erétil em um paciente, medicamento para diminuir os efeitos colaterais associados com os agentes terapêuticos para tratar a disfunção sexual em um paciente, método para fabricação de um medicamento para tratamento da disfunção sexual de um paciente responsivo marginalmente ao inibidor de pde5, e uso do peptìdeo ac-nle-ciclo (-asp-his-d-phe-arg-trp-lys) -0h na perparação de um medicamento
PA8484001A1 (es) Suministro de agente activo aerosolizado modulado con resistencia de flujo.
CO5060522A1 (es) Administracion de un agente activo en aerosol
CO5611174A2 (es) Inhalador de polvo seco
UY27875A1 (es) Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae
AR048718A1 (es) Uso de formulaciones de meloxicam en medicina veterinaria
HN2008001666A (es) Derivados acidos de cicloalquilamino
AR100368A1 (es) Tratamiento de trastornos respiratorios
PE20211805A1 (es) Formulaciones de un inhibidor de axl/mer
ES2139673T3 (es) Utilizacion de norastemizol para el tratamiento de rinitis alergica.
BR112015027247A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas
PE20050189A1 (es) Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local
BR112023022649A2 (pt) Uso de 5-nitro-8-hidroxiquinolina
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
DOP2002000454A (es) Uso de una combinacion de compuesto en un inhalador de polvo seco.
BR0212077A (pt) Compostos de aminopirróis como agentes antiinflamatórios
UY27442A1 (es) Uso de una combinación de compuestos en un inhalador de polvo seco..
UY27441A1 (es) Uso de compuestos en un inhalador de polvo seco.
CO2020000292A2 (es) Preparación medicinal combinada para tratar infecciones virales
HN1999000087A (es) Aparato dispensador de polvo seco y metodos de uso del mismo

Legal Events

Date Code Title Description
FD Lapse